NCT01858961 - Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients | Biotech Hunter

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Hepatitis C, Chronic

Interventions

DRUG

BI 201335

Once a day

DRUG

ribavirin

Twice a day

DRUG

BI 207127

Twice a day

DRUG

Telaprevir

Three times a day

DRUG

ribavirin

Twice a day

DRUG

Pegylated Interferon

Once a week

Trial Locations (12)

1241.37.61002 Boehringer Ingelheim Investigational Site, Westmead

1241.37.61001 Boehringer Ingelheim Investigational Site, Adelaide

1241.37.61003 Boehringer Ingelheim Investigational Site, Fitzroy

1241.37.34010 Boehringer Ingelheim Investigational Site, Alzira

1241.37.34005 Boehringer Ingelheim Investigational Site, Barcelona

1241.37.34002 Boehringer Ingelheim Investigational Site, L'Hospitalet Llobregat (bcn)

1241.37.34001 Boehringer Ingelheim Investigational Site, Madrid

1241.37.34003 Boehringer Ingelheim Investigational Site, Madrid

1241.37.34004 Boehringer Ingelheim Investigational Site, Madrid

1241.37.34006 Boehringer Ingelheim Investigational Site, Valencia

1241.37.46002 Boehringer Ingelheim Investigational Site, Lund

1241.37.46001 Boehringer Ingelheim Investigational Site, Stockholm